Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

References

• Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428–1434.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Robertson LE, O’Brien S, et al. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995;18:493–496.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Jones JA, Byrd JC. How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 2014;123:1455–1460.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912–4920.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008;49:1074–1080.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196–203.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda W, Plunkett W, et al. Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). Blood 2009;114(Suppl. 1): Abstract 3443.
   Google Scholar
• Tonino SH, van Gelder M, Eldering E, et al. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 2010;24:652–654.
   PubMed Web of Science ®Google Scholar
• Hallaert DY, Jaspers A, van Noesel CJ, et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112: 5141–5149.
   PubMed Web of Science ®Google Scholar
• Mous R, Jaspers A, Luijks DM, et al. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 2009;23:1352–1355.
   PubMed Web of Science ®Google Scholar
• Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999;23:127–136.
   PubMed Web of Science ®Google Scholar
• Dicker F, Kater AP, Prada CE, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006;108:3450–3457.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Veerman AJ, Pieters R, et al. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995;19:175–181.
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Lens SM, Medema RH, et al. Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. Int Immunol 2002;14:973–982.
   PubMed Web of Science ®Google Scholar
• Sayan AE, Paradisi A, Vojtesek B, et al. New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun 2005;330:186–193.
   PubMed Web of Science ®Google Scholar
• Suo G, Jiang Y, Cowan B, et al. Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod 2009;81:749–758.
   PubMed Web of Science ®Google Scholar
• Tonino SH, van Laar J, van Oers MH, et al. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 2011;30:701–713.
   PubMed Web of Science ®Google Scholar
• Ali MS, Khan SR, Ojima H, et al. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate) 2(9-ethylguanine)Cl]NO 3.H2O. J Inorg Biochem 2005;99:795–804.
   PubMed Web of Science ®Google Scholar
• Bertilaccio MT, Scielzo C, Muzio M, et al. An overview of chronic lymphocytic leukaemia biology. Best Pract Res Clin Haematol 2010;23:21–32.
   PubMed Web of Science ®Google Scholar
• Munk Pedersen I, Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004;45:2365–2372.
   PubMed Web of Science ®Google Scholar
• Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660–1668.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071–5082.
   PubMed Web of Science ®Google Scholar
• Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;399:806–809.
   PubMed Web of Science ®Google Scholar
• Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005;5:251–265.
   PubMedGoogle Scholar
• Million K, Horvilleur E, Goldschneider D, et al. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells. Int J Oncol 2006;29:147–154.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005;96:729–737.
   PubMed Web of Science ®Google Scholar
• Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809–819.
   PubMed Web of Science ®Google Scholar
• Rossi M, De Laurenzi V, Munarriz E, et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005;24:836–848.
   PubMed Web of Science ®Google Scholar
• Preyer M, Shu CW, Wang JY. Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals. Cell Death Differ 2007;14:1139–1148.
   PubMed Web of Science ®Google Scholar
• Lanasa MC. Novel insights into the biology of CLL. Hematology Am Soc Hematol Educ Program 2010:70–76.
   Google Scholar
• Van Gelder M, Ghidey W, Chamuleau MED, et al. R-DHAP immunochemotherapy is an effective remission-induction treatment for CLL patients with fludarabine refractory disease with or without deletion 17p, enabling the majority to proceed to allogeneic stem cell transplantation [abstract]. Blood 2013;122(Suppl. 1): Abstract 2883.
   Google Scholar
• Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001;8:1213–1223.
   PubMed Web of Science ®Google Scholar
• Rufini A, Agostini M, Grespi F, et al. p73 in cancer. Genes Cancer 2011;2:491–502.
   PubMedGoogle Scholar
• Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5’ CpG island methylation. Cancer Res 1999;59:3352–3356.
   PubMed Web of Science ®Google Scholar
• Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113–1120.
   PubMed Web of Science ®Google Scholar
• Martinez-Delgado B, Melendez B, Cuadros M, et al. Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer 2002;102:15–19.
   PubMed Web of Science ®Google Scholar
• Pluta A, Nyman U, Joseph B, et al. The role of p73 in hematological malignancies. Leukemia 2006;20:757–766.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Castro JE, Aguillon R, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010;24:1893–1900.
   PubMed Web of Science ®Google Scholar
• Sampath D, Calin GA, Puduvalli VK, et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009;113:3744–3753.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619–2629.
   PubMed Web of Science ®Google Scholar
• Alonso R, Lopez-Guerra M, Upshaw R, et al. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood 2009;114:1563–1575.
   PubMed Web of Science ®Google Scholar
• Seeliger B, Wilop S, Osieka R, et al. CpG island methylation patterns in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:419–426.
   PubMed Web of Science ®Google Scholar
• Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 2000;407:645–648.
   PubMed Web of Science ®Google Scholar
• Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000;26:464–469.
   PubMed Web of Science ®Google Scholar
• Lam EW, Choi MS, van der Sman J, et al. Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. J Biol Chem 1998;273:10051–10057.
   PubMed Web of Science ®Google Scholar
• Lam EW, Glassford J, van der Sman J, et al. Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur J Immunol 1999;29:3380–3389.
   PubMed Web of Science ®Google Scholar